Does TELMISARTAN Cause Malignant neoplasm progression? 18 Reports in FDA Database
Lower Your Cholesterol — The Natural Way
The Oxidized Cholesterol Strategy: a science-backed plan for heart health.
According to the FDA Adverse Event Reporting System (FAERS), 18 reports of Malignant neoplasm progression have been filed in association with TELMISARTAN (telmisartan). This represents 0.3% of all adverse event reports for TELMISARTAN.
18
Reports of Malignant neoplasm progression with TELMISARTAN
0.3%
of all TELMISARTAN reports
5
Deaths
13
Hospitalizations
How Dangerous Is Malignant neoplasm progression From TELMISARTAN?
Of the 18 reports, 5 (27.8%) resulted in death, 13 (72.2%) required hospitalization, and 1 (5.6%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TELMISARTAN. However, 18 reports have been filed with the FAERS database.
What Other Side Effects Does TELMISARTAN Cause?
Drug ineffective (685)
Dizziness (569)
Dyspnoea (556)
Headache (508)
Fall (500)
Nausea (486)
Hypertension (477)
Blood pressure increased (473)
Diarrhoea (467)
Malaise (458)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which TELMISARTAN Alternatives Have Lower Malignant neoplasm progression Risk?
TELMISARTAN vs TELOTRISTAT ETHYL
TELMISARTAN vs TEMAZEPAM
TELMISARTAN vs TEMODAR
TELMISARTAN vs TEMOZOLOMIDE
TELMISARTAN vs TEMSIROLIMUS